JVJonathan L. Vandergrift

Jonathan L. Vandergrift

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jonathan L. Vandergrift has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Adoption of Internal Medicine Milestone Ratings and Changes in Bias Against Black, Latino, and Asian Internal Medicine Residents

    by Bradley M. Gray, Rebecca S. Lipner, Robert O. Roswell, Alicia Fernandez, Jonathan L. Vandergrift, Marcella Alsan

    The 2014 adoption of the Milestone ratings system may have affected evaluation bias against minoritized groups. To assess bias in internal medicine (IM) residency knowledge ratings against Black or Latino residents-who are underrepresented in medicine (URiM)-and Asian residents before versus after Milestone adoption in 2014. Cross-sectional and interrupted time-series comparisons. U.S. IM residencies. 59 835 IM residents completing residencies during 2008 to 2013 and 2015 to 2020. Adoption of the Milestone ratings system. Pre-Milestone (2008 to 2013) and post-Milestone (2015 to 2020) bias was estimated as differences in standardized knowledge ratings between U.S.-born and non-U.S.-born minoritized groups versus non-Latino U.S.-born White (NLW) residents, with adjustment for performance on the American Board of Internal Medicine IM certification examination and other physician characteristics. Interrupted time-series analysis measured deviations from pre-Milestone linear bias trends. During the pre-Milestone period, ratings biases against minoritized groups were large (-0.40 SDs [95% CI, -0.48 to -0.31 SDs; P < 0.001] for URiM residents, -0.24 SDs [CI, -0.30 to -0.18 SDs; P < 0.001] for U.S.-born Asian residents, and -0.36 SDs [CI, -0.45 to -0.27 SDs; P < 0.001] for non-U.S.-born Asian residents). These estimates decreased to less than -0.15 SDs after adoption of Milestone ratings for all groups except U.S.-born Black residents, among whom substantial (though lower) bias persisted (-0.26 SDs [CI, -0.36 to -0.17 SDs; P < 0.001]). Substantial deviations from pre-Milestone linear bias trends coincident with adoption of Milestone ratings were also observed. Unobserved variables correlated with ratings bias and Milestone ratings adoption, changes in identification of race/ethnicity, and generalizability to Milestones 2.0. Knowledge ratings bias against URiM and Asian residents was ameliorated with the adoption of the Milestone ratings system. However, substantial ratings bias against U.S.-born Black residents persisted. None.


  • Geriatricians, general internists, and potentially inappropriate medications for a national sample of older adults

    by Jonathan L. Vandergrift, Weifeng Weng, Bruce Leff, Bradley M. Gray

    Background: Older adults are often prescribed medications that are potentially dangerous and geriatricians have specialized training in treating polypharmacy that may benefit these patients. To examine this, we compared potentially inappropriate medication (PIM) prescribing rates between geriatricians and similar general internists in the United States. Methods: Using national cross‐sectional data from 2013 to 2019, we compared annual PIM prescribing rates between 2815 outpatient geriatricians certified by the American Board of Internal Medicine in 1994–2018 and general internists matched 1:1 on IM certification exam score and year, residency exam pass rate, gender, and US birth and/or US medical school. PIM prescribing was based on the Healthcare Effectiveness Data and Information Set (HEDIS) PIM physician annual prescribing measures which consider medications flagged as potentially inappropriate in the American Geriatric Society Beers Criteria® guideline. We also examined prescribing of appropriate alternative medications. Prescribing rates were calculated as the percentage a physician's patients with Medicare fee‐for‐service part D enrollment seen in the outpatient setting in a given year (mean: 150 patients per physician) with a PIM prescription they prescribed. Results: Across 30,677 physician‐year observations, geriatricians were 16.7% less likely (95% confidence interval (CI): −19.8 to −13.7, p < 0.001) to prescribe a PIM (7.2% versus 8.7% of patients respectively) and 2.7% more likely (95% CI: 0.8 to 4.5, p = 0.004) to prescribe an appropriate alternative medication (52.0% versus 50.7% of patients respectively). Lower PIM prescribing was observed for most medication sub‐types including central nervous system, anticholinergic, pain, and endocrine medications. In sensitivity analyses, differences in prescribing were similar when comparing recently trained physicians with more experienced physicians. Conclusion: Findings suggest geriatricians in the United States prescribe PIMs at lower rates than general internists. This highlights the value geriatricians provide as well as opportunities to embed key principles of geriatric care into internal medicine training and health care delivery systems.


  • Relationship Between Participation in ASCO's Quality Oncology Practice Initiative Program and American Board of Internal Medicine's Maintenance of Certification Program

    by Robert D. Siegel, Elizabeth Garrett-Mayer, Rebecca S. Lipner, Mary May Priscilla Kozlik, Jonathan L. Vandergrift, Stephanie T.S. Crist, Ronald C. Chen, Anne C. Chiang, Arif H. Kamal

    Medical oncologists have a variety of options for demonstrating proficiency in providing high-quality patient care. Perhaps, the best-known opportunity for demonstrating individual expertise and lifelong learning is the American Board of Internal Medicine (ABIM) maintenance of certification (MOC) program. At the practice level, ASCO has offered the Quality Oncology Practice Initiative (QOPI) as a means of optimizing cancer care delivery. In this study, we assess the association between active involvement in MOC on an individual basis and whether that individual’s practice is involved with the QOPI program. We evaluated 13,600 US medical oncologists initially certified by the ABIM and divided them into those initially certified before 1990 (the year in which ABIM started to require periodic recertification), those from 1990 to 2007, and those from 2008 to 2016. It was then determined which of these had let their certificates expire by 2020. These data were then compared with practices that participated in QOPI from 2017 to 2019, resulting in the matching of 97% of physicians Of individuals initially certified before 1990 (and technically with lifelong certification), 22% were in QOPI practices. Among those who did not have lifelong certification, there was an association between QOPI participation and maintenance of ABIM certification. For those initially certified between 1990 and 2007, 35% of oncologists with up-to-date ABIM certification were in QOPI practices, whereas only 11% with expired ABIM certification were QOPI participants (P < .0001). For those in the 2008-2016 category, the numbers were 36% v 16%, respectively (P < .0001). Our analysis identifies a relationship between participation in these ABIM and ASCO proficiency programs. The reasons for this are likely complex and based on a variety of institutional, professional, monetary, and personal factors.

  • The association between physician knowledge and inappropriate medications for older populations

    by Jonathan L. Vandergrift, Weifeng Weng, Bradley M. Gray

    Background: Older patients are often prescribed potentially inappropriate medications (PIMs) given their age. We measured the association between a physician's general knowledge and their PIM prescribing. Methods: Using a 2013–2017 cross‐sectional design, we related a general internist's knowledge ( n = 8196) to their prescribing of PIMs to fee‐for‐service Medicare beneficiaries, age ≥ 66 years with part D coverage, which they saw in the outpatient setting the year after their exam ( n = 875,132). Physician knowledge was based on the American Board of Internal Medicine's (ABIM) Internal Medicine Maintenance of Certification (IM‐MOC) exam scores. Medications included 72 PIMs from the American Geriatric Society's Beers Criteria and appropriate alternatives to these medications. Logistic regressions controlled for physicians practice/training characteristics and patient‐risk factors. Results: Annually, 11.0% of patients received a PIM and 57.2% received an appropriate alternative medication. Patients seen by physicians scoring in the top versus bottom quartile were 8.6% less likely (95% confidence interval [CI]: −12.7 to −4.5, p < 0.001) to be prescribed a PIM and 4.7% more likely (95% CI: 1.7 to 7.6, p = 0.001) to be prescribed an appropriate alternative medication. The difference in PIM prescribing grew to 12.1% fewer (95% CI: −15.1 to −9.1) patients when limiting the sample to the 58.9% of patients being prescribed a PIM or appropriate alternative medication. Among patients receiving any medication, this was similar to the percent difference in PIM prescribing between solo and large practices (≥50 physicians, −10.2%, 95% CI: 13.6–6.5, p < 0.001) or between group and academic practices (−11.7%, 95% CI: −15.3 to −7.9, p < 0.001). PIM prescribing was more positively associated with patient characteristics including age, gender, and total number of medications prescribed. Conclusions: Better physician general knowledge, as measured by an ABIM exam, was associated with fewer PIM prescriptions. Future research should examine whether general educational interventions, such as MOC, effect PIM prescribing.


  • Opportunities for Maintenance of Certification to Better Reflect Scope of Practice Among Medical Oncologists

    by Jonathan L. Vandergrift, Bradley M. Gray, Brendan J. Barnhart, Lorna A. Lynn, Rebecca S. Lipner

    PURPOSE: Critics argue that the American Board of Internal Medicine’s medical oncology Maintenance of Certification examination requires medical oncologists with a narrow scope of practice to spend time studying material that is no longer relevant to their practice. However, no data are available describing the scope of practice for medical oncologists. METHODS: Using Medicare claims, we examined the scope of practice for 9,985 medical oncologists who saw 8.6 million oncology conditions in 2016, each of which was assigned to 1 of 23 different condition groups. Scope of practice was then measured as the percentage of oncology conditions within each of the 23 groups. We grouped physicians with similar scopes of practice by applying K-means clustering to the percentage of conditions seen. The scope of practice for each physician cluster was determined from the cancers that encompassed the majority of average oncology conditions seen among physicians composing the cluster. RESULTS: We found 20 distinct scope-of-practice clusters. The largest (n = 6,479 [65.5%]) had a general oncology scope of practice. The remaining physicians focused on a narrow scope of cancers, including 22.6% focused on ≥ 1 solid tumors and 11.9% focused on hematologic malignancies. The largest focused cluster accounted for 7.7% of physicians focused on breast cancer. CONCLUSION: A single American Board of Internal Medicine Maintenance of Certification assessment in medical oncology is most appropriate for approximately 65% of certified medical oncologists’ practices. However, the addition of assessments focused on breast cancer and hematologic malignancies could increase this figure to upwards of 85% of certified medical oncologists.


    • 1 October 2019
      • Vol. 25  (10) , 497-+

    Physician Clinical Knowledge, Practice Infrastructure, and Quality of Care

    by Jonathan L. Vandergrift, Bradley M. Gray

    OBJECTIVES: To understand if and how one dimension of physician skill, clinical knowledge, moderates the relationship between practice infrastructure and care quality. STUDY DESIGN: We included 1301 physicians who certified in internal medicine between 1991 and 1993 or 2001 and 2003 and took the American Board of Internal Medicine (ABIM)'s Maintenance of Certification (MOC) exam and completed ABIM's diabetes or hypertension registry during their 10-year recertification period between 2011 and 2014. Composite quality scores (overall, process, and intermediate outcome) were based on chart abstractions. Practice infrastructure scores were based on a web-based version of the Physician Practice Connections Readiness Survey. Our measure of clinical knowledge was drawn from MOC exam performance. METHODS: We regressed a physician's composite care quality scores against the interaction between their practice infrastructure and MOC exam scores with controls for physician, practice, and patient panel characteristics. RESULTS: We found that a physician's exam performance significantly moderated the association between practice infrastructure and care quality (P for interaction = .007). For example, having a top quintile practice infrastructure score was associated with a quality care score that was 7.7 (95% CI, 4.3-11.1) percentage points (P < .001) higher among physicians scoring in the top quintile of their MOC exam, but it was unrelated (0.7 [95% CI, -3.8 to 5.3] percentage points; P = .75) to quality among physicians scoring in the bottom quintile on the exam. CONCLUSIONS: Physician skill, such as clinical knowledge, is important to translating patient-centered practice infrastructure into better care quality, and so it may become more consequential as practice infrastructure improves across the United States.


  • Do State Continuing Medical Education Requirements for Physicians Improve Clinical Knowledge?

    by Jonathan L. Vandergrift, Bradley M. Gray, Weifeng Weng

    Objective: To evaluate the effect of state continuing medical education (CME) requirements on physician clinical knowledge.Data Sources: Secondary data for 19,563 general internists who took the Internal Medicine Maintenance of Certification (MOC) examination between 2006 and 2013.Study Design: We took advantage of a natural experiment resulting from variations in CME requirements across states over time and applied a difference‐in‐differences methodology to measure associations between changes in CME requirements and physician clinical knowledge. We measured changes in clinical knowledge by comparing initial and MOC examination performance 10 years apart. We constructed difference‐in‐differences estimates by regressing examination performance changes against physician demographics, county and year fixed effects, trend–state indicators, and state CME change indicators.Data Collection: Physician data were compiled by the American Board of Internal Medicine. State CME policies were compiled from American Medical Association reports.Principal Findings: More rigorous CME credit‐hour requirements (mostly implementing a new requirement) were associated with an increase in examination performance equivalent to a shift in examination score from the 50th to 54th percentile.Conclusions: Among physicians required to engage in a summative assessment of their clinical knowledge, CME requirements were associated with an improvement in physician clinical knowledge.


    • 1 November 2016
      • Vol. 22  (11) , e375-e381

    The role of internal medicine subspecialists in patient care management.

    by Jonathan L Vandergrift, Bradley M Gray, James D Reschovsky, Eric S Holmboe, Rebecca D Lipner

    To understand the clinical roles in which internal medicine (IM) subspecialists engage, especially those involving ongoing patient management. Measures of physician clinical roles were based on survey responses collected from 8020 mid-career IM subspecialists who registered for the American Board of Internal Medicine maintenance of certification program (86% registration/response rate) between 2009 and 2013. Each subspecialist reported their percentage of clinical time in 5 clinical roles: primary, principal, longitudinal consultative, medical consultative, and procedural care. We characterized an IM subspecialist's clinical role focus as those roles that composed a majority of their clinical time. Most IM subspecialists reported spending a majority of their time performing 1 (65%) or 2 (31%) clinical roles. Most (54%) reported a clinical role focused on ongoing patient care management roles, including principal care (eg, total responsibility for a specific condition, 23%), longitudinal consultative care (eg, shared care, 21%); or a mixed clinical role focus composed of both principal and longitudinal consultative care (8%). We also found that physicians focused on ongoing patient care management roles represent a significant percentage of physicians within most IM subspecialties (ranging from 19% to 88% across subspecialties). A subspecialist's clinical role focus is an important practice characteristic, and many subspecialists perceive themselves as playing a significant role in care management. These findings suggest there are opportunities to incorporate subspecialists into newer payment and care delivery reforms; they also bring to light reasons that training and certification programs should consider the different clinical role foci subspecialists adopt.


  • Open Access

    Time to Adjuvant Chemotherapy for Breast Cancer in National Comprehensive Cancer Network Institutions

    by Jonathan L. Vandergrift, Joyce C. Niland, Richard L. Theriault, Stephen B. Edge, Yu-Ning Wong, Loretta S. Loftus, Tara M. Breslin, Clifford A. Hudis, Sara H. Javid, Hope S. Rugo, et al.

    High-quality care must be not only appropriate but also timely. We assessed time to initiation of adjuvant chemotherapy for breast cancer as well as factors associated with delay to help identify targets for future efforts to reduce unnecessary delays. Using data from the National Comprehensive Cancer Network (NCCN) Outcomes Database, we assessed the time from pathological diagnosis to initiation of chemotherapy (TTC) among 6622 women with stage I to stage III breast cancer diagnosed from 2003 through 2009 and treated with adjuvant chemotherapy in nine NCCN centers. Multivariable models were constructed to examine factors associated with TTC. All statistical tests were two-sided. Mean TTC was 12.0 weeks overall and increased over the study period. A number of factors were associated with a longer TTC. The largest effects were associated with therapeutic factors, including immediate postmastectomy reconstruction (2.7 weeks; P < .001), re-excision (2.1 weeks; P < .001), and use of the 21-gene reverse-transcription polymerase chain reaction assay (2.2 weeks; P < .001). In comparison with white women, a longer TTC was observed among black (1.5 weeks; P < .001) and Hispanic (0.8 weeks; P < .001) women. For black women, the observed disparity was greater among women who transferred their care to the NCCN center after diagnosis (Pinteraction = .008) and among women with Medicare vs commercial insurance (Pinteraction < .001). Most observed variation in TTC was related to use of appropriate therapeutic interventions. This suggests the importance of targeted efforts to minimize potentially preventable causes of delay, including inefficient transfers in care or prolonged appointment wait times.


  • Concordance to National Comprehensive Cancer Network (NCCN) clinical practice guideline (GL) drug therapy recommendations for metastatic breast cancer: An analysis from the commercial managed care claims database PharMetrics (PM).

    by E. M. Lepisto, K. Tangirala, J. L. Vandergrift, J. S. McClure, D. L. McNally, C. D. Mullins, B. S. Seal

    1032 Background: The NCCN GLs provide the standard of care for the treatment of women with metastatic breast cancer (mBC). The primary aim of the current project is to assess concordance between the NCCN GL recommendation for drug therapy and care received using the PM database (DB). The PM is a patient (pt) care DB that incorporates medical and pharmaceutical claims data for younger managed-care patients. Methods: Claims for pts diagnosed with metastatic breast cancer from 2002 to 2008 were examined. Overall, 26,476 women with metastatic breast cancer were identified. Median age was 40 years. Results: 26,260 (99%) patients were identified as premenopausal with 7,005 (28%) receiving antiestrogen (AE) therapy. Until 2005, the NCCN GLs recommended luteinizing hormone-releasing hormone (LHRH) agonists as an optional compliment to AE therapy for mBC. Prior to 2005, 37 of 2,838 pts (1%) received LHRH agonists. After 2005, 3% received nonconcordant therapy with LHRH agonists. After 2005, the NCCN GLs recommend bevacizumab therapy only with paclitaxel for treatment of mBC. 9,378 pts received antineoplastic therapy after 2005. Of this, 2.1% of pts were treated with bevacizumab therapy, 75% of which received therapy per NCCN GL recommendations. The use of bisphosphonates for pts with bone metastases is a category 1 recommendation in the NCCN GLs. Only 44% of patents with bone disease received GL concordant care. Additional drug therapy measures are in development. Comparisons with SEER/Medicare are being analyzed. Conclusions: Less than half of mBC pts with bone disease received care concordant with the NCCN GLs. Few patients received bevacizumab therapy with moderate concordance. Almost all patients receiving AE therapy did not receive LHRH agonists as per NCCN GL recommendations.